secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inspire Medical Systems, Inc. (INSP)
CIK:        0001609550
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001609550-24-000050
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance
--------------------------------------------------------------------------------

- Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).
- Operating income $14.3M vs loss $13.5M; net income $18.5M, diluted EPS $0.60 vs loss $0.29.
- Raises FY 2024 revenue guidance to $793-798M (27-28% growth) and EPS guidance to $1.20-1.40.
- Activated 66 new U.S. centers (total 1,371); created 13 new sales territories (total 323).
- Received FDA approval for Inspire V neurostimulation system; gross margin steady at 84.1%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609550/000160955024000050/0001609550-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609550/000160955024000050/insp-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001609550-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer